| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |